Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-05-31
Based on 366 first isolates · MED-B · Febrile UTI / pyelonephritis · 2025-06-01 → 2026-05-31
Internal medicine B
Per-organism detail: MED-B urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
ceftriaxone 81 % (77 %–85 %)
Not covered: Enterococcus faecalis (8 %), Pseudomonas aeruginosa (5 %), Staphylococcus aureus (2 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
89 %
88 %
n = 34
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
84 %
82 %
n = 34
nitrofurantoin NIT
trend · Escherichia coli not for this site
82 %
82 %
n = 34
ceftriaxone CRO
trend · Escherichia coli
81 %
85 %
n = 34
mecillinam MEC
trend · Escherichia coli not for this site
80 %
82 %
n = 34
ciprofloxacin CIP
trend · Escherichia coli
79 %
71 %
n = 34
76 %
76 %
n = 34
trimethoprim TMP
trend · Escherichia coli not for this site
71 %
68 %
n = 34
45 %
35 %
n = 34
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
10 %
9 %
n = 34
5 %
6 %
n = 34
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
2 %
3 %
n = 34

Most likely organisms for this profile

Escherichia coli
59 %
Klebsiella pneumoniae
11 %
Enterococcus faecalis
8 %
Proteus mirabilis
7 %
Citrobacter freundii
5 %
Pseudomonas aeruginosa
5 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.